The full results of the phase III REVERSE-IT trial continue to show that ticagrelor (Brilinta)-reversing therapy bentracimab ...

Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in ...

The first clinical guidance for cardiogenic shock will be presented at the American College of Cardiology Scientific Session ...

yet cardiac surgeons are not particularly willing to operate in the acute MI setting. In terms of left main disease, the very first patient described with cardiogenic shock was by Herrick in 1912 ...

Patients who have acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) experience elevated mortality rates ...

The Guam Memorial Hospital Authority said its acquisition of its first-ever intra-aortic balloon pump is a significant ...

Cardiogenic shock, often caused by heart failure ... and rapidly increase systolic blood pressure and improve cardiac output ...

Cardiogenic shock remains a challenging clinical syndrome characterized by critically impaired cardiac output, systemic hypoperfusion, and high mortality ...

A MACHINE learning model can accurately predict in-hospital mortality in patients with Takotsubo cardiomyopathy (broken heart ...

Cardiogenic shock is defined as reduced cardiac output due to inability of the heart to pump adequate blood in the presence of a normal blood volume.

The company’s lead asset, Istaroxime, is a first-in-class, dual-acting agent being developed to improve blood pressure and cardiac function in patients with cardiogenic shock. A second ...

Cardiogenic shock occurs when the heart is not able to pump enough blood to generate adequate cardiac output to maintain normal blood pressure. This frequently occurs in the setting of a large ...